Renal denervation: Potential impact on hypertension in kidney disease?

Nephrology Dialysis Transplantation

Volumn 26, Issue 9, 2011, Pages 2732-2734

  Blankestijn, Peter J ^a   Ritz, Eberhard ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

chronic kidney disease; hypertension; renal denervation; sympathetic activity

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY DISEASE; KIDNEY ISCHEMIA; NONHUMAN; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC HYPERACTIVITY; SYMPATHETIC TONE;

ANIMALS; HUMANS; HYPERTENSION, RENAL; KIDNEY; KIDNEY DISEASES;

EID: 80053196411     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr190     Document Type: Article

References (18)

1. Ritz E, Rump LC. Control of sympathetic activity-new insights; new therapeutic targets? Nephrol Dial Transplant 2010; 25: 1048-1050
2. Siddiqi L, Joles JA, Grassi G et al. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? J Hypertens 2009; 27: 1341-1349
3. Ye S, Gamburd M, Mozayeni P et al. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998; 11: 723-728 (Pubitemid 28313692)
4. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25: 878-882
5. Hendel MD, Collister JP. Renal denervation attenuates long-term hypertensive effects of angiotensin II in the rat. Clin Exp Pharmacol Physiol 2006; 33: 1225-1230 (Pubitemid 44923912)
6. Crowley SD, Gurley SB, Herrera MJ et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 2006; 103: 17985-17990 (Pubitemid 44852272)
7. Converse RL Jr., Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918 (Pubitemid 23006966)
8. Hausberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-1979 (Pubitemid 35176304)
9. Wenting GJ, Blankestijn PJ, Poldermans D et al. Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important. Am J Cardiol 1987; 59: 92D-97D (Pubitemid 17071273)
10. Klein IH, Ligtenberg G, Neumann J et al. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14: 3239-3244 (Pubitemid 37509299)
11. Matsukawa T, Gotoh E, Minamisawa K et al. Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol 1991; 261: R690-R696
12. Vonend O, Rump LC, Ritz E. Sympathetic overactivity-the Cinderella of cardiovascular risk factors in dialysis patients. Semin Dial 2008; 21: 326-330
13. Mancia G, Grassi G, Giannattasio C et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34: 724-728 (Pubitemid 29501288)
14. Schlaich MP, Sobotka PA, Krum H et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009; 54: 1195-1201
15. Ritz E. New approaches to pathogenesis and management of hypertension. Clin J Am Soc Nephrol 2009; 4: 1886-1889
16. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281
17. Schlaich MP, Sobotka PA, Krum H et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-934
18. Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909